Limerick, PA. April 18, 2018 – Rockland Immunochemicals, Inc. announced today that Chief Science Officer, Dr. Carl Ascoli testified at the National Academies of Sciences, Engineering and Medicine’s third of six public session on Reproducibility and Replicability in Science on April 18th.

The National Academies are charged by Congressional mandate to explore the issues of reproducibility and replication in scientific and engineering research. The committee, composed of 15 subject matter experts, will assess what is known and identify areas that need more information regarding issues of replication and reproducibility; consider if the lack of replication and reproducibility impacts the health of science and the public’s perception; and draw conclusions and make recommendations to Congress that may have consequences affecting levels of government funding.

The open session portion of the April 18th meeting featured speakers from various disciplines including physics, engineering, life sciences, statistical analysis and economics. Dr. Ascoli presented to...

Ascoli went on to explain that Rockland and other leading antibody manufacturers and resellers, along with funding agencies and some journals, are embracing change that will make a difference. For instance: (1) better use of standards and controls can be made when collecting experimental data; (2) the ‘knowledge gap” that has resulted from outsourcing antibody technology can be addressed; (3) funding agencies can require precise description of reagents and methods to foster reproducibility; (4) journals can publish all necessary details of reagents and protocols critical for reproducibility; and (5) antibody manufacturers and resellers can adopt immunoassay specific validation guidelines and provide greater transparency when describing antibody production, screening methods and release criteria.

Opinion leaders testifying at this session challenged whether a “crisis” of reproducibility exists, as some have claimed in the literature, especially when considering that the clear majority of research performed results in the collection of high quality data sufficient to support and reproduce scientific claims. For instance, the pace at which new treatments have accelerated from the bench to the clinic has resulted in an explosion of breakthroughs in medicine, and antibodies are central to the discovery, diagnosis and cure of many diseases that just a decade ago were considered to have poor patient outcomes.

The root causes of data irreproducibility identified at this meeting were biases in experimental design, biases in statistical analysis, the resultant inaccuracies of mathematical standards and constants, and the inherent variability that exists when biological reagents are used. Focus on these causative factors is imperative as the stakes are high. One economist speculated that the potential economic impact of data irreproducibility, especially for pre-clinical and clinical applications, ranges from 190 to 380 billion US dollars, cumulatively.

The committee was given a timeline to assess issues pertaining to reproducibility and replication, hear testimony by subject matter experts, deliberate and complete their investigations within approximately 18 months of the start of activities in October 2017. At the conclusion, a written report will be issued to Congress that includes an assessment of current activities to improve reproducibility and replication highlighting examples of good practices and examine factors that adversely affect reproducibility and replication.

Interested in reading more?

The Scientist ARCHIVES

Become a Member of

Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member?